Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENGN NASDAQ:LENZ NASDAQ:MESO NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENGNenGene$5.97+4.6%$4.17$2.65▼$11.00$291.81M-0.39216,061 shs51,547 shsLENZLENZ Therapeutics$40.01-3.2%$36.06$16.53▼$42.77$1.18B0.45430,779 shs315,659 shsMESOMesoblast$15.46+4.3%$14.57$6.00▼$22.00$1.90B2.26219,601 shs162,435 shsVIRVir Biotechnology$4.79-4.2%$5.06$4.16▼$14.45$694.58M1.281.48 million shs1.33 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENGNenGene+4.55%+9.94%+62.23%+83.69%-10.76%LENZLENZ Therapeutics-3.19%+0.96%+5.71%+38.16%+83.03%MESOMesoblast+4.32%+6.25%-4.86%+31.35%+148.55%VIRVir Biotechnology-4.20%-7.71%+5.97%-6.08%-40.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENGNenGene$5.97+4.6%$4.17$2.65▼$11.00$291.81M-0.39216,061 shs51,547 shsLENZLENZ Therapeutics$40.01-3.2%$36.06$16.53▼$42.77$1.18B0.45430,779 shs315,659 shsMESOMesoblast$15.46+4.3%$14.57$6.00▼$22.00$1.90B2.26219,601 shs162,435 shsVIRVir Biotechnology$4.79-4.2%$5.06$4.16▼$14.45$694.58M1.281.48 million shs1.33 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENGNenGene+4.55%+9.94%+62.23%+83.69%-10.76%LENZLENZ Therapeutics-3.19%+0.96%+5.71%+38.16%+83.03%MESOMesoblast+4.32%+6.25%-4.86%+31.35%+148.55%VIRVir Biotechnology-4.20%-7.71%+5.97%-6.08%-40.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENGNenGene 3.00Buy$21.00251.76% UpsideLENZLENZ Therapeutics 3.00Buy$49.6023.97% UpsideMESOMesoblast 3.20Buy$18.0016.43% UpsideVIRVir Biotechnology 2.90Moderate Buy$17.30261.17% UpsideCurrent Analyst Ratings BreakdownLatest ENGN, MESO, VIR, and LENZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.009/12/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$19.00 ➝ $18.009/8/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.009/3/2025VIRVir BiotechnologyEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$12.008/27/2025VIRVir BiotechnologyBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$12.00 ➝ $14.008/5/2025MESOMesoblastCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/31/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.00 ➝ $49.007/31/2025LENZLENZ TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$39.00 ➝ $40.007/28/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $48.007/18/2025MESOMesoblastJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold7/11/2025VIRVir BiotechnologyRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENGNenGeneN/AN/AN/AN/A$5.35 per shareN/ALENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/AMESOMesoblast$17.20M115.05N/AN/A$4.67 per share3.31VIRVir Biotechnology$74.21M8.97N/AN/A$8.35 per share0.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENGNenGene-$55.14M-$1.90N/AN/AN/AN/A-39.86%-34.15%N/ALENZLENZ Therapeutics-$49.77M-$1.90N/AN/AN/AN/A-25.63%-24.43%11/5/2025 (Estimated)MESOMesoblast-$102.14MN/A0.00N/AN/AN/AN/AN/AN/AVIRVir Biotechnology-$521.96M-$4.00N/AN/AN/A-2,895.94%-50.22%-40.78%10/30/2025 (Estimated)Latest ENGN, MESO, VIR, and LENZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/11/2025Q3 2025ENGNenGene-$0.5084-$0.57-$0.0616-$0.57N/AN/A8/6/2025Q2 2025VIRVir Biotechnology-$0.72-$0.80-$0.08-$0.80$2.38 million$1.21 million7/30/2025Q2 2025LENZLENZ Therapeutics-$0.58-$0.53+$0.05-$0.53$5.00 million$5.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENGNenGene$1.5826.48%N/AN/A N/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENGNenGene0.0910.3410.34LENZLENZ TherapeuticsN/A20.5420.54MESOMesoblast0.111.991.77VIRVir BiotechnologyN/A7.017.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENGNenGene64.16%LENZLENZ Therapeutics54.32%MESOMesoblast1.43%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipENGNenGene10.40%LENZLENZ Therapeutics6.90%MESOMesoblast18.80%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENGNenGene3151.11 million45.79 millionN/ALENZLENZ Therapeutics11028.52 million26.55 millionN/AMESOMesoblast80128.00 million103.93 millionOptionableVIRVir Biotechnology580138.92 million116.69 millionOptionableENGN, MESO, VIR, and LENZ HeadlinesRecent News About These Companies84,398 Shares in Vir Biotechnology, Inc. $VIR Purchased by Cinctive Capital Management LPSeptember 8, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Down 6% on Insider SellingSeptember 6, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Now Covered by Analysts at Evercore ISISeptember 6, 2025 | americanbankingnews.comVicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) StockSeptember 5, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Price Up 8% - Here's WhySeptember 5, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Now Covered by Evercore ISISeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 185,933 Shares of Vir Biotechnology, Inc. $VIRSeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Sells 542,000 Shares of Vir Biotechnology, Inc. $VIRSeptember 4, 2025 | marketbeat.comEvercore ISI Group Initiates Coverage of Vir Biotechnology (VIR) with Outperform RecommendationSeptember 3, 2025 | msn.comThe Play On Vir BiotechnologySeptember 3, 2025 | seekingalpha.comVir Biotechnology initiated with an Outperform at Evercore ISISeptember 3, 2025 | msn.comVir Biotechnology, Inc. $VIR Shares Bought by Russell Investments Group Ltd.September 2, 2025 | marketbeat.comWalleye Capital LLC Sells 183,494 Shares of Vir Biotechnology, Inc. $VIRSeptember 1, 2025 | marketbeat.comNuveen LLC Takes $2.32 Million Position in Vir Biotechnology, Inc. $VIRSeptember 1, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Up Following Analyst UpgradeAugust 29, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Rating Increased to Buy at Bank of AmericaAugust 29, 2025 | marketbeat.comVir Biotechnology stock soars after BofA upgrade, $14 targetAugust 28, 2025 | investing.comVir Stock Soars After BofA Boosts Rating on Liver TherapyAugust 28, 2025 | finance.yahoo.comVir upgraded at BoA on potential for liver disease asset; shares surge 13%August 28, 2025 | msn.comVir Biotechnology, Inc. $VIR Shares Bought by Charles Schwab Investment Management Inc.August 28, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by BrokeragesAugust 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025New Age Warfare: Anduril Is the Hype, AeroVironment Is the BuyBy Jeffrey Neal Johnson | August 28, 2025Take the Money and Run: Strategy Stock Looks Tapped OutBy Gabriel Osorio-Mazilli | September 9, 2025AeroVironment Is a Hot Buy With a Double-Digit UpsideBy Thomas Hughes | September 11, 2025ENGN, MESO, VIR, and LENZ Company DescriptionsenGene NASDAQ:ENGN$5.97 +0.26 (+4.55%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$5.97 0.00 (0.00%) As of 09/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.LENZ Therapeutics NASDAQ:LENZ$40.01 -1.32 (-3.19%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$40.53 +0.52 (+1.31%) As of 09/15/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Mesoblast NASDAQ:MESO$15.46 +0.64 (+4.32%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$15.86 +0.40 (+2.55%) As of 09/15/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Vir Biotechnology NASDAQ:VIR$4.79 -0.21 (-4.20%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$4.76 -0.03 (-0.52%) As of 09/15/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
